Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 9/2014

01-09-2014 | Research Commentary

Letter regarding Chen et al. entitled “A systematic review of vascular endothelial growth factor expression as a biomarker of prognosis in patients with osteosarcoma”

Authors: Li-hong Liu, Hui Li, Tao Xiao

Published in: Tumor Biology | Issue 9/2014

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Chen D, Zhang YJ, Zhu KW, Wang WC. A systematic review of vascular endothelial growth factor expression as a biomarker of prognosis in patients with osteosarcoma. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2013;34(3):1895–9.CrossRef
Metadata
Title
Letter regarding Chen et al. entitled “A systematic review of vascular endothelial growth factor expression as a biomarker of prognosis in patients with osteosarcoma”
Authors
Li-hong Liu
Hui Li
Tao Xiao
Publication date
01-09-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 9/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2536-2

Other articles of this Issue 9/2014

Tumor Biology 9/2014 Go to the issue

Research Article

Efficacy of S-1 plus nedaplatin compared to standard second-line chemotherapy in EGFR-negative lung adenocarcinoma after failure of first-line chemotherapy

Research Article

E-cadherin gene methylation in lung cancer

Research Article

Prediction of thyroid extracapsular extension with cervical lymph node metastases (ECE-LN) by CEUS and BRAF expression in papillary thyroid carcinoma

Research Article

Epigenetic alteration of p16 and retinoic acid receptor beta genes in the development of epithelial ovarian carcinoma

Research Article

Association of caspase9 promoter polymorphisms with the susceptibility of AML in south Indian subjects

Editorial

Hepatic resection associated with good survival for selected patients with multinodular hepatocellular carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits